Unbalanced presence of TGF-b opposes effective cell proliferation and differentiation processes, necessary to replace damaged epithelia. TGF-b also retains arrested cells in a fibrotic phenotype responsible for irreversible scarring. In order to identify prospective molecular targets to prevent the effect of TGF-b during CKD, we studied the signaling pathways responsible for the antiproliferative effect of this cytokine. Methods: Tubule epithelial HK2 and MDCK cells were treated with TGF-b (or not as control) to study cell proliferation (by MTT), cell signaling (by Western blot), cell cycle (by flow cytometry) and apoptosis (DNA fragmentation). Results: TGF-b fully activates the ALK-5 receptor pathway, whereas it has no effect on the ALK-1 and MAPK pathways in both HK2 and MDCK cells. Interestingly, TGF-b exerts an antiproliferative effect only on MDCK cells, through a cytostatic effect in G0/G1. Inhibition of the ALK-5 pathway with SB431542 prevents the cytostatic effect of TGF-b on MDCK cells. Conclusion: Activation of the ALK-5 pathway is not sufficient for the antiproliferative effect of TGF-β. The presence of undetermined permissive conditions or absence of undetermined inhibitory conditions seems to be necessary for this effect. The ALK-5 pathway appears to provide targets to modulate fibrosis, but further research is necessary to identify critical circumstances allowing or inhibiting its role at modulating tubule epithelial cell proliferation and tubule regeneration in the context of CKD progression.
Introduction
Chronic kidney disease (CKD) is a global epidemic with an increasing prevalence worldwide [1] . CKD comprises a group of pathologies in which the renal excretory function progressively and irreversibly decreases as a consequence of nephron loss due to glomerular or tubule cell deletion, fibrosis affecting both the glomeruli and the tubules, and renal vasculature alterations [2] [3] [4] . Patients may die to secondary conditions, the most important of which being cardiovascular events, or need renal replacement therapy in the form of renal transplant or dialysis [5] . It is estimated that 10-20% of the adult population have some degree of CKD, and that dialysis (applied on 0.1% of the population) consumes about 2% of the total health expenditure in many developed countries [6] .
Traditionally, it was thought that the fibrotic process associated to CKD had its origin exclusively in the activation of local fibroblasts. However, other renal cell types have been lately identified as sources of fibrotic tissue components. Tubular epithelial cells can undergo epithelial-to-mesenchymal transition (EMT) to become myofibroblasts [7, 8] . Compared to tubule epithelial cells, myofibroblasts bear enhanced motility, increased proliferative and contractile capacity, and overproduce extracellular matrix elements contributing to fibrosis [4] . Tubular EMT has also been implicated in tubular tissue repair. Through the EMT, undamaged tubular epithelial cells would acquire the necessary phenotype to migrate and proliferate to substitute for death cells at neighbouring injury sites. At such points, dedifferentiated cells would then re-differentiate into TECs and synthesize extracellular matrix (ECM) components to rebuild the ECM and basement membrane, in a reverse process of mesenchymal to epithelial transition (MET) [4] . According to this model, under a pathological cytokine imbalance scenario typical of the CKD, MET would become skewed or interrupted and, consequently, dedifferentiated cells would not undergo the redifferentiation process and would continue to abnormally and ectopically produce ECM, leading to fibrosis and scarring [9] . A critical contributor for repair interruption may be a defective proliferation of tubular epithelial cells. The arrested tubular cells up regulate profibrotic cytokine production [10, 11] . Accordingly, cell cycle-arresting mediators may alter the repair process and facilitate fibrosis.
Transforming growth factor-β (TGF-β) has been shown to exert both anti-proliferative and pro-fibrotic effects [2, 4] , and EMT [12] . TGF-β is synthesized by various cell types including lymphocytes, macrophages, fibroblasts, myocytes, chondrocytes, astrocytes, epithelial cells, kidney cells and platelets [13] . TGF-b induces the synthesis of ECM, and stimulates the production of protease inhibitors preventing normal enzymatic breakdown and turnover of the ECM [14] . TGF-β membrane receptor complex comprises two families of proteins with serin-threonin kinase activity, namely type II (TβRII) and type I (TβRI) receptors. TβRI includes activin-like kinase (ALK) receptors. TGF-β binds to TβRII, which then recruits TβRI. The complex phosphorylates and activates several intracellular signaling cascades, including the small mothers against decapentaplegic (Smads); mitogen-activated protein kinases, such as extracellular regulated kinase (ERK), p38 and Jun kinase; and integrin-linked kinase (ILK). These effectors modulate the expression of target genes [15, 16] . Measurement of the expression level of these target genes serves to determine the full activation (or lack of) of specific pathways. Activation of the ALK-1-Smad-1/5 pathway, ultimately leads to the expression of plasminogen activator inhibitor 1 (PAI-1); whereas activation of the ALK-5-Smad-2/3 pathway leads to inhibitor of differentiation 1 (Id-1) expression [17] .
Identification of the signaling pathways involved in the antiproliferative and profibrotic effects of TGF-b may lead to better understanding the pathological mechanisms underlying CKD progression. In the present study we aimed at unraveling the role of the ALK-5 pathway in the antiproliferative effect of TGF-β1 in renal tubule cells, in order to identify new pharmacological targets for more selective and specific therapeutic and preventive strategies for CKD. 
Materials and Methods
All reagents were purchased from Sigma (Madrid, Spain), except where otherwise indicated.
Cell culture Tubular cell lines, namely Human Kidney (HK2) cells and Madin-Darby Canine Kidney (MDCK) cells, were used and grown in an atmosphere of 95% air and 5% CO 2 at 37°C. MDCK were grown in DMEM medium (Bio Whittaker Labs, Rockland ME, USA) supplemented with 10% fetal calf serum (FCS, Bio Whittaker Labs), 0.66 mg/mL penicillin and 60 mg/mL streptomycin sulfate (Bio Whittaker Labs), HK2 were grown in RPMI 1640 (Bio Whittaker Labs) supplemented with 10% FCS, 1 mM L-glutamine, 0.66 mg/mL penicillin, 60 mg/ mL streptomycin sulfate, 5 mg/mL insulin, 5 mg/mL transferrin and 5 ng/mL selenium. Cells were seeded in 100 mm Petri dishes (Nunc, Roskilde, Denmark). MDCK and HK2 cells were treated for 15, 30, 60, 120 minutes and 24, 48, 96 hours with TGF-β1 (0.1, 0.3 and 1 ng/mL) (Upstate-Millipore, Madrid, Spain). In some experiments, the ALK-5 pathway was inhibited with the ALK-5 inhibitor SB431542 (Tocris Bioscience, Bristol, UK). Representative photographs (x200) were obtained of MDCK and HK2 cells treated with 1 ng/ mL TGF-ß1 (or vehicle, as control). Cell proliferation and cell death, and the underlying signaling involved were studied.
Cell viability/proliferation by the MTT assay
Viable cell number was determined by incubating cell cultures with 0.5 mg/mL 3-[4.5-dimethylthiazol-2-yl]-2.5-diphenyl tetrazolium bromide (MTT) for 4 h. Then, 10% SDS in 0.01M HCl was added 1:1 (vol/vol) and left overnight at 37°C. Finally, absorbance was measured at 570 nm.
Cell viability by propidium iodide exclusion
Cells were incubated for 15 min with 50 lg/mL propidium iodide (PI, Sigma Aldrich) in the dark. Immediately, cells were analyzed by flow cytometry for PI fluorescence (FLH-2) in a FACScalibur cytometer (BD Pharmingen).
Cell cycle analysis
Thirty minutes before harvest, 10 µM 5-bromo-2-deoxyuridine (BrdU, Sigma Aldrich) was added to the cell culture. Subsequently, cells were fixed in ice-cold 70% ethanol overnight and stained with 0.01 mg/ mL anti-BrdU-FITC antibody (Abcam, Cambridge, United Kingdom). Then, 0.01 mg/mL PI was added to cell suspensions and 1 hour later they were analyzed by flow cytometry (FACScalibur, BD Pharmingen) with the CellQuest software. Singlet discrimination was done by means of an FL2-A versus FL2-W representation.
DNA fragmentation DNA fragmentation was determined by ELISA with the commercial kit Cell Death Detection Plus (Roche Diagnostics, Barcelona, Spain) according to the manufacturer's instructions. Ten micrograms of protein were used from each cell extract.
Nuclear integrity analysis
Cells in cover slips were fixed with 4% paraformaldehyde, washed with phosphate buffered saline with calcium and magnesium (PBS Ca-Mg: 1mM CaCl 2 , 1 mM MgSO4, 0.81% ClNa, 2.6 mM PO 4 H 2 K, 4.1 mM PO 4 HNa 2 ), permeabilyzed with 0.1% Triton X-100, 0.2% BSA and 0.5% sodium azide, quenched with NH 4 Cl 50 mM in PBS Ca-Mg. Nuclei staining was performed by 5 min incubation with 2mM Hoechst 33258 (Molecular Probes, Madrid, Spain) in a dark chamber. Cover slips were mounted on slides using Prolong gold antifade (Molecular Probes, Madrid, Spain). Fluorescence images were taken using a Zeiss Axiovert 200M microscope and a Zeiss LSM 510 confocal module (Zeiss, Madrid, Spain), with a HeNe laser with 543-excitation for rhodamine and Hg laser with 365-excitation.
Western blot
Protein extracts were obtained in extraction buffer (140 mM NaCl, 20 mM Tris-HCl pH=7.5, 0.5 M ethylenediaminetetraacetic acid -EDTA-, 10% glycerol, 1% Igepal CA-630, 1 µg/mL aprotinin, 1 µg/mL leupeptin, 1 µg/mL pepstatin A, 1 mM phenylmethylsulphonyl fluoride -PMSF-). Thirty micrograms from each Figure 1 shows the effect of incubating HK-2 and MDCK cells during short and long periods of time (up to 2 hours and up to 4 days, respectively) on intracellular signaling known to be activated by TGF-b through the stimulation of the ALK-1 and ALK-5 receptors. In both of cell lines, TGF-b activated Smad-2, which indicated prior activation of the ALK-5 receptor. This was evidenced by an increased phosphorylation of Smad-2, and an increased level of PAI-1, the protein product of a target gene in the Smad-2 pathway. Smad-1, Erk and Akt were not further activated by TGF-b, as revealed by the absence of additional phosphorylation of these proteins after short and long term exposure to the cytokine. This suggests that, in the present conditions, TGF-b1 does not activate the ALK-1/Smad-1 pathway.
Results

TGF-b1 fully activates the ALK-5/Smad-2 pathway in MDCK and HK2 cells
Fig. 1. Intracellular signaling activated
by TGF-b1 in HK2 and MDCK cells. Representative images of Western blot analysis (of n=3 independent experiments) of the amount of P-Smad2, P-Smad1, P-Akt, P-Erk, PAI-1 and total Erk of cell extracts from MDCK and HK2 cells treated for 15, 30, 60 or 120 minutes with 0 or 1 ng/mL TGF-ß1 (a) and 24, 48 or 96 hours with 0 or 1 ng/mL TGF-β1 (b).
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TGF-β1 reduces the proliferation of MDCK but not of HK2 cells
Incubation of MDCK cells with TGF-b reduced proliferation in a concentration-and time-dependent manner (Fig. 2b) . However, TGF-b exerted no effect on the proliferation of HK2 cells (Fig. 2a) . This antiproliferative effect on MDCK cells correlated with a cell cycle arrest in G0/G1 phase, as demonstrated by flow-cytometry analysis of PI-stained cells (Fig.  3a) , and lower levels of cyclins E and A in MDCK cells, and not in HK2 cells (Fig. 3b) .
The ALK-5 pathway is necessary for the antiproliferative effect of TGF-β in MDCK cells but not in HK2 cells
The ALK-5 inhibitor SB431542 inhibits Smad-2 activation. This is shown by the inhibition of TGF-b1-induced Smad-2 phosphorylation, both in MDCK and HK2 cells, as revealed by Western blot (Fig. 4b) . Inhibition of the ALK-5 pathway with SB431542 inhibits the antiproliferative effect of TGF-b1 of MDCK cells, and has no effect on the proliferation of HK2 cells (Fig. 4a) . This indicates that activation of the ALK-5 pathway is necessary but not sufficient for the antiproliferative effect of TGF-b1. In fact, the ALK-5/Smad-2 pathway is also fully activated in HK2 cells, with no consequence on cell proliferation.
The antiproliferative effect of TGF-b is not associated to cell death
No cell death or apoptosis was induced by TGF-b1 treatment in MDCK and HK2 cells, indicating that all the antiproliferative effect induced by this cytokine was due to cell cycle slow down. As shown in Fig. 5 , no morphological signs of cell death or cell debris were observed after 4 days of treatment with TGF-b1. No signs of nuclear alterations or internucleosomal DNA fragmentation (two hallmarks of apotosis) were detected by microscopy and ELISA, respectively (Fig. 5) .
Discussion
In this study we show that activation of the ALK-5 pathway is necessary for the antiproliferative effect of TGF-β1 in MDCK cells, but plays no role in HK2 cells. These findings indicate that the ALK-5-mediated pathways might be necessary for the antiproliferative effect of this cytokine on tubule cells; but also, that other determinants are necessary to be present or to be absent to allow TGF-β1 to curtail tubule cell proliferation through ALK-5 activation.
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Identification of mechanisms leading to proliferation of remnant tubular epithelial cells is a key to understanding normal and aberrant renal tissue repair, which in turn is key to understanding CKD progression [11, 18] . TGF-b has different biological functions, which occasionally result in opposed effects depending on the cell type and biological scenario. Overall, inhibition of TGF-b action has proved beneficial effects in the context of both acute [19] and chronic [2, 20] renal damage. This benefit has been ascribed to the inhibition of the profibrotic and proapoptotic effects of TGF-b. TGF-b-induced fibrosis is well characterized, and has been recognized as an important mechanism of renal tissue derangement and scarring during CKD (reviewed in 2 and 20] . Direct induction of apoptosis by TGF-b has been suggested [21] , but also called into question [4] . TGF-b exerts also an antiproliferative effect on many cell types and biological circumstances, although its role in the pathophysiology of renal damage has not been fully delineated. Probably, during a correct renal tissue repair course, TGF-b may have an important role in, for example, stimulating the production of extracellular matrix components by re-differentiated tubular epithelial cells, in order to reconstitute the extracellular matrix and basement membrane [4, 22] . However, its presence must be avoided in other phases of the repair course, or its effects must be appropriately modulated or inhibited to obviate un-desired effects. In addition, the presence or effect of TGF-b must terminate at due time in order to prevent tissue fibrosis and derangement. Other cytokines present both in normal and aberrant tissue repair are known to oppose and appropriately and timely modulate specific effects of TGF-b [4] . These include bone morphogenetic protein 7 (BMP7) [23, 24] and hepatic growth factor (HGF) [25, 26] . Accordingly, as a general concept, a cytokine imbalance may skew or even interrupt tissue repair at any stage of the course and contribute to the progression of CKD [27] . Interestingly, an agonist of the BMP7 receptor ALK-3 reduced renal injury in five different models of acute and chronic renal injury [23] . This protection was not exerted in animals genetically manipulated whose tubular epithelium lacked ALK-3 [23] .
An excessive or insufficiently balanced presence of TGF-b during the proliferation phase might cause skewing of tissue repair, which would lead to further fibrosis [4] . Our results indicate that activation of the Smad-2 pathway is critical for the antiproliferative effect of TGF-b in MDCK cells. Inhibition of the Alk-5-Smad-2 pathway abrogates the antiproliferative effect of TGF-b in these cells. However, full activation of the Alk-5-Smad-2 pathway (up to gene expression modulation) has no effect on the proliferation of HK2 cells. This might indicate that the ALK-5-Smad-2 pathway is differently linked to other cellular mediators controlling cell proliferation in MDCK and HK2 cells. Or, alternatively, that additional conditions or mediators need to be present or absent in order for the ALK-5 pathway to mediate the antiproliferative effect of TGF-β. These additional players may be induced also by TGF-β (differentially in each cell type); or they may be intrinsically specific of the cell strain, or be expressed or repressed differentially under determined circumstances. The final or net effect of TGF-b is determined by the sum of the signals activated. In this sense signaling through the Smad pathway or the Ras-ERK pathway has been shown to be dependent on p53 [28] . For example, in the context of embryo development, TGF-b-induced cytostasis has been linked to its capacity to bind p53. In this situation, TGF-b-p53 interaction is only possible after N-terminal phosphorylation of p53, in a Ras/mitogen-activated protein kinase (MAPK)-dependent manner [29] [30] [31] . In our experimental system, the Ras-ERK pathways is not further activated by TGF-b in any of the two cell lines, indicating that this is not the additional pathway controlling the effect of this cytokine of cell proliferation.
In conclusion, although the ALK-5 pathway appears to offer some potential as a target to modulate CKD progression, further investigation is needed to identify the circumstances that modulate the net effect of the ALK-5 pathway in normal human tubule epithelial cells and, importantly, also under CKD circumstances.
